Nanoparticle-delivered RNA interference drug stops head and neck cancer growth

April 6, 2012

( -- A nanoparticle drug delivery vehicle for small interfering RNA molecules (siRNA), that is already being tested in human clinical trials, now shows promise for the treatment of head and neck cancer. Dong Shin, of Emory University, and Mark E. Davis, of the Nanosystems Biology Cancer Center at the California Institute of Technology, led this study. The results were published in the Journal of Controlled Release.

Drugs based on siRNA technology are designed to turn off the production of specific proteins that are critically involved in a disease such as cancer. While a significant body of evidence has shown this approach to targeting critical disease pathways can be highly effective, siRNA molecules themselves do not survive in the blood stream. Dr. Davis and his colleagues have long been leaders in the effort to use tumor-targeted nanoparticles to protect siRNAs from degradation and deliver them to where they are needed in the body.

In this study Dr. Davis's group, which had previously developed a nanoparticle that encapsulates a siRNA agent aimed at a protein known as RRM2, has teamed up with Dr. Shin's group to evaluate the effectiveness of these particles in head and neck cancer. RRM2, when over expressed in these tumor types, plays an active role in tumor progression and in the development of . Initial tests on head and neck tumor cells growing in culture showed that this construct was taken up by the , and as a result growth of the cells was inhibited substantially. The investigators obtained similar results when they tested the drug on cultured non-small cell .

Based on these findings, the researchers tested the siRNA-loaded nanoparticle in a mouse model of human . One intravenous injection of the drug shut down production of RRM2 for at least 10 days, with the nanoparticle being present in the tumor for three days. Four injections given over 10 days triggered a substantial amount of tumor cell death and significantly reduced tumor progression. The researchers note that they did not observe any adverse effects or changes in body weight during the course of therapy. They also showed that the drug had no effect on RRM2 production in the liver.

This work, which is detailed in a paper titled, "Systemic delivery of siRNA nanoparticles targeting RRM2 suppresses head and neck tumor growth," was supported in part by the NCI Alliance for Nanotechnology in Cancer, a comprehensive initiative designed to accelerate the application of nanotechnology to the prevention, diagnosis, and treatment of cancer.

Explore further: Targeted nanoparticles incorporating siRNA offer promise for cancer treatment

More information: View abstract here.

Related Stories

Pack 'Em In -- Gold Nanoparticles Improve Gene Regulation

February 23, 2009

Investigators at Northwestern University have found that packing small interfering RNA (siRNA) molecules onto the surface of a gold nanoparticle can protect siRNAs from degradation and increase their ability to regulate genes ...

Polymeric nanoparticles attack head and neck cancer

July 15, 2011

Head and neck cancer, the sixth most common cancer in the world, has remained one of the more difficult malignancies to treat, and even when treatment is successful, patients suffer severely from the available therapies. ...

Recommended for you

Graphene under pressure

August 25, 2016

Small balloons made from one-atom-thick material graphene can withstand enormous pressures, much higher than those at the bottom of the deepest ocean, scientists at the University of Manchester report.

Designing ultrasound tools with Lego-like proteins

August 25, 2016

Ultrasound imaging is used around the world to help visualize developing babies and diagnose disease. Sound waves bounce off the tissues, revealing their different densities and shapes. The next step in ultrasound technology ...

Nanovesicles in predictable shapes

August 25, 2016

Beads, disks, bowls and rods: scientists at Radboud University have demonstrated the first methodological approach to control the shapes of nanovesicles. This opens doors for the use of nanovesicles in biomedical applications, ...

'Artificial atom' created in graphene

August 22, 2016

In a tiny quantum prison, electrons behave quite differently as compared to their counterparts in free space. They can only occupy discrete energy levels, much like the electrons in an atom - for this reason, such electron ...

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

not rated yet Apr 07, 2012
Will this same system work on other tumours? In other words can we manufacture nano particles that are tumour specific.
If so this could be a really important piece of work.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.